Literature DB >> 6711573

Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2.

M S Ernstoff, J M Kirkwood.   

Abstract

Bone marrow aspirates and biopsy specimens in 12 patients with solid tumors treated with recombinant interferon alpha-2, 3 to 100 X 10(6) units per day, were evaluated in a blinded fashion both before and after therapy. No change in overall cellularity was noted. There was significant accumulation of lymphocytes (3.9 +/- 1 versus 10 +/- 2.7, p = 0.036), decrease in eosinophils (4.5 +/- 0.8 versus 2.2 +/- 0.7, p = 0.011), and decrease in red cell precursors (36.4 +/- 3.1 versus 28 +/- 4.2, p = 0.091). A trend to accumulation of white cell precursors, metamyelocytes (8.8 +/- 1.4 versus 12 +/- 2.0, p = NS), and band forms (10.0 +/- 1 versus 12.1 +/- 1.2, p = NS) was noted. No megaloblastosis, ring sideroblasts, or block in differentiation was observed. These observations are most consistent with reversible block in release of cells from the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711573     DOI: 10.1016/0002-9343(84)90282-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Interferon for treatment: the dust settles.

Authors:  D Galvani; S D Griffiths; J C Cawley
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

3.  Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens.

Authors:  M Schmid; A Kreil; W Jessner; M Homoncik; C Datz; A Gangl; P Ferenci; M Peck-Radosavljevic
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  Risks and benefits of interferon-alpha in the treatment of hepatitis.

Authors:  M Pardo; E Marriott; M C Moliner; J A Quiroga; V Carreño
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

5.  A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data.

Authors:  M N Saleh; A F LoBuglio; R H Wheeler; K J Rogers; A Haynes; J Y Lee; M B Khazaeli
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B.

Authors:  M Sata; Y Yano; Y Yoshiyama; T Ide; R Kumashiro; H Suzuki; K Tanikawa
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 8.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.